|Systematic (IUPAC) name|
|14px (what is this?)|
Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea or vomiting and dizziness.
Mechanisms of action
Like other H2 receptor antagonists it prevents the secretion of gastric acid. It also activates calcitonin gene related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of H. pylori to gastric cells.